Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056368 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
NCT00056368 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 256 participants.
The verdict
NCT00056368, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
Study Summary
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.
Interventions
- DRUG Fluconazole
- DRUG Anidulafungin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056368
The ClinicalTrials.gov registry entry for NCT00056368 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluconazole is the first listed.
NCT00056368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056368 about?
NCT00056368 is a clinical study titled "The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis". Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.
What is the current status of trial NCT00056368?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2003-03. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00056368?
The interventions under investigation include: Fluconazole (DRUG), Anidulafungin (DRUG).
Who is sponsoring clinical trial NCT00056368?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.